Telomir Pharmaceuticals, Inc. (TELO)
NASDAQ: TELO · Real-Time Price · USD
1.450
+0.030 (2.11%)
At close: Apr 28, 2026, 4:00 PM EDT
1.480
+0.030 (2.05%)
After-hours: Apr 28, 2026, 7:51 PM EDT

Telomir Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
8.110.012.370.020.01
Research & Development
2.442.241.570.830.13
Operating Expenses
10.5412.243.940.850.14
Operating Income
-10.54-12.24-3.94-0.85-0.14
Interest Expense
--4.34-1.64--
Interest & Investment Income
0.130.05---
EBT Excluding Unusual Items
-10.41-16.53-5.59-0.85-0.14
Other Unusual Items
---7.49--
Pretax Income
-10.41-16.53-13.07-0.85-0.14
Net Income
-10.41-16.53-13.07-0.85-0.14
Net Income to Common
-10.41-16.53-13.07-0.85-0.14
Shares Outstanding (Basic)
32302727-
Shares Outstanding (Diluted)
32302727-
Shares Change (YoY)
7.16%8.18%1.77%--
EPS (Basic)
-0.33-0.56-0.48-0.03-
EPS (Diluted)
-0.33-0.56-0.48-0.03-
EBIT
-10.54-12.24-3.94-0.85-0.14
Source: S&P Capital IQ. Standard template. Financial Sources.